Background: Familial hypercholesterolaemia increases the risk for cardiovascular disease. The primary aim of the present study was to describe sex differences in incidence and prevalence of cardiovascular disease leading to hospitalisation in a complete cohort of genotyped familial hypercholesterolaemia patients. Design and methods: In this registry study data on 5538 patients with verified genotyped familial hypercholesterolaemia were linked to data on all Norwegian cardiovascular disease hospitalisations, and hospitalisations due to preeclampsia/eclampsia, congenital heart defects and diabetes. Results: During 1994-2009 a total of 1411 of familial hypercholesterolaemia patients were hospitalised, and ischaemic heart disease was reported in 90% of them. Mean (SD) age at first hospitalisation and first re-hospitalisation was 45.1 (16.5) and 47.6 (16.3) years, respectively, with no sex differences (P ¼ 0.66 and P ¼ 0.93, respectively). More men (26.9%) than women (24.1%) with familial hypercholesterolaemia were hospitalised (P ¼ 0.02). The median (25th-75th percentile) number of hospital admissions was four (two to seven) per familial hypercholesterolaemia patient, with no sex differences (P ¼ 0.87). Despite having familial hypercholesterolaemia at the time of hospitalisation, the diagnosis of familial hypercholesterolaemia was registered in only 45.7% of the patients at discharge. Conclusion: Most cardiovascular disease hospitalisations were due to ischaemic heart disease. Familial hypercholesterolaemia patients were first time hospitalised at age 45.1 years, with no significant sex differences in age, which are important novel findings. The awareness and registration of the familial hypercholesterolaemia diagnosis during the hospital stays were disturbingly low.
Introduction
Cardiovascular disease (CVD) is a leading cause of morbidity and mortality, 1 accounting for 46% of all deaths in Europe. 1 Despite decreases in CVD mortality rates in most European countries, CVD hospitalisations have increased since the early 2000s, and are among the highest ranked disease categories in hospital discharges. 1, 2 Hospital discharge data reflect the burden of CVD morbidity. 1 CVD is the most common cause of all hospitalisations in Norway, of which coronary heart disease (CHD) dominates. 3 Annually, about 15,000 Norwegian patients suffer from acute myocardial infarction (AMI), of whom 36% are women. 4 Although the incidence rate of AMI declined from 2001 to 2009 in Norway, 5 an 11% increase in hospitalisation rates was observed in persons less than 45 years of age. 5 Familial hypercholesterolaemia (FH) is an inherited disorder with increased low-density lipoprotein (LDL) cholesterol, 6, 7 and a high risk of premature CVD, particularly at a young age. 8, 9 Before the age of 40 years, the risk of CVD death is increased five to 20-fold, but as the FH patients get older their risk gradually approaches that of the general population. 8, 10, 11 A European study has suggested that the prevalence of FH is inversely related to age in CHD patients, with a putative prevalence of 1:5 in those with CHD less than 50 years of age, 12 much higher than the prevalence in the general population, which is estimated to be about 1:200. 13 Once diagnosed with FH, patients are recommended lipid-lowering treatment according to the European Society of Cardiology guidelines. 13 A 76% overall risk reduction in CHD in statin-treated FH patients has been reported, suggesting these patients no longer have a risk of myocardial infarction significantly different from that of the general population. 14 To date, important data have been missing to answer questions on how modern cholesterol-lowering treatment affects CVD morbidity in FH women and FH men and the prognosis for these individuals. This study aimed to investigate sex differences in incidence and prevalence of CVD leading to hospitalisation in a complete cohort of genotyped FH patients. We specifically studied if specific subtypes of CVD are more prevalent in relation to sex.
Methods Approvals
This study was performed in accordance with the Declaration of Helsinki and approved by the Regional Committee for Medical and Health Research Ethics, South-East Norway (case no. 2011/ 1343) and the Data Protection Official at Oslo University Hospital.
Study design
This was a registry study of all genotyped FH patients in Norway from 1 January 1992 until 1 May 2014. All FH patients living in this time period were observed for hospitalisations in the time period from 1 January 1994 through to 31 December 2009. The study endpoint was determined as 31 December 2009. The primary outcome was first time hospitalisation due to CVD, and comparison of events between FH women and FH men.
The Unit for Cardiac and Cardiovascular Genetics Registry and the Cardiovascular Disease in Norway database
Study data were derived from the National Unit for Cardiac and Cardiovascular Genetics (UCCG) Registry and the Cardiovascular Disease in Norway (CVDNOR) database.
In Norway, genetic testing for FH has been performed since 1992. All patients with FH mutations are included in the UCCG Registry after written informed consent. All FH patients are heterozygote except 11 patients who are homozygote. 8 In CVDNOR (www.cvdnor.no) all hospital stays recorded with a cardiovascular discharge diagnosis or pre-eclampsia/eclampsia, congenital heart defects and diabetes were retrieved retrospectively from the patient administrative systems at all Norwegian somatic hospitals from 1 January 1994 throughout 2009. 22 During this period, 4.3 million hospitalisations were registered of which women accounted for 46.8%. 15 There were in total 1.3 million patients hospitalised (51.3% women) with a CVD-related diagnosis or procedure code, 15 of which a third of them had CHD. 15 The mean (SD) age at first time admission with a CVD-related diagnosis was 64.9 (20.2) years: 64.0 (19.0) years in men and 66. 0 (21.3) years in women. 16 The mean number of hospital admissions was 3.2: 3.5 for men and 3.0 for women, respectively. 16 An incident AMI was defined as the first AMI event in an individual with no prior hospitalisation due to AMI during the previous seven years. 16 A recurrent AMI was defined as a new event occurring over 28 days after the first event. 16 If hospitalisation for AMI occurred within 28 days of the first event, it was defined as part of the same event. 16 An AMI event with percutaneous coronary intervention (PCI) was defined as hospitalisation due to AMI and PCI procedure code given within 28 days from AMI hospitalisation date. 16 An AMI event with coronary artery bypass grafting (CABG) was defined as a CABG procedure within eight weeks from the AMI event. 16 The coding system used for hospitalisations was the International Classification of Diseases (ICD). 16 From 1994 throughout 1995, the 9th revision was used, and from 1996 the 10th. The diagnostic codes were categorised as either main or secondary diagnosis. For all CVD-related diagnostic and treatment procedures the coding systems: the Norwegian classification of medical procedures, 3rd edition, version 1995 (SIF95), the NOMESCO classification of surgical procedures (NCSP) and the Norwegian classification of medical procedures (NCMP) were used. In 2006 the NCSP and the NCMP were merged. 17 The main discharge diagnosis was defined as the diagnosis requiring the most resources during a hospital stay. In cases in which the same patient was admitted to one hospital ward and later transferred to other wards within the same hospital stay, only the main discharge diagnosis from the first hospital ward was reported. If a patient was re-admitted to the hospital within 24 hours after discharge, this new hospitalisation was defined as belonging to the first. If re-admission occurred more than 24 hours after discharge from the first, this was defined as a new hospitalisation. 16 
Data collection
Data on hospitalisations in the FH cohort were retrieved from 1 January 1994 through to 31 December 2009. Variables taken from the UCCG Registry were sex, birth year, date and age of inclusion in the registry. This information was linked to CVDNOR data on age at first hospitalisation and rehospitalisations, admissions and discharge dates, department and ward codes as well as transfer dates and whether the admission was acute or elective. Furthermore, data on CVD-related procedures performed during hospital stays were extracted. 16, 17 The definition of diagnoses and CVD-related procedures are given in Table 1 .
Statistical analysis
Descriptive data are presented as means (SDs) for normal distributed continuous variables and frequencies (%) for categorical variables. For skewed data, the median (25th and 75th percentile) is reported.
Age at hospitalisation was calculated by subtracting year of birth from year of hospitalisation. Re-admission was defined as more than one hospital stay. Time from inclusion in the UCCG Registry was given according to sex and year of birth. Sex differences in characteristics between groups were tested by independent t-test for continuous variables and the chi-square test for categorical variables. For skewed distributions, the Wilcoxon rank-sum test was used. As repeated hospitalisations of the same individual leads to dependence between observations of hospitalisation, we applied repeated measures logistic regression to test sex differences. Odds ratios (ORs) with 95% confidence intervals (CIs) are presented. A Wald test was applied to study interaction between age and sex in the analysis of CVD hospitalisations ( Table 5 ). The total numbers of FH patients hospitalised according to attained age intervals were calculated. All P values less than 0.05 were considered statistically significant. The analyses were performed using STATA 13.1, 12-core Parallel Edition, and the Statistical Package of Social Sciences (SPSS Inc, Chicago, IL, USA) version 22.0.
Results
The FH study sample The mean (SD) age at inclusion in the UCCG Registry, reflecting the age at the time of genetic FH diagnosis, was 33.8 (19.0) years: 32.5 (18.6) years for men and 35.0 (19.4) years for women (P < 0.001). The median (25 th -75th percentile) time to study endpoint from the genetically verified FH diagnosis was 5 (1-9) years with no sex differences (P ¼ 0.92).
During 1994-2009, 1411 (25.4%) of all genotyped FH patients in Norway were hospitalised, of whom 1130 (80.1%) were re-hospitalised. More FH men (26.9%) than FH women (24.1%) (P ¼ 0.02) were hospitalised. Re-hospitalisation was as common among men as women (P ¼ 0.71). The characteristics of the hospitalised patients are summarised in Table 2 .
There were no sex differences in the proportion of hospital admissions in the UCCG Registry (P ¼ 0.87) or in the type of hospitalisations (P ¼ 0.86 for acute and P ¼ 0.78 for elective admissions), of which elective admissions were dominating ( Table 2) .
Those who had been hospitalised were older at the time of genetic diagnosis than those who had not been hospitalised: mean (SD) 47.6 (16.7) years versus 29.2 (17.3) years (P < 0.001), respectively. The patients were genotyped 8.8 (5.5) years prior to study endpoint (men 9.1 (5.7) and women 8.5 (5.3), P ¼ 0.04) ( Table 2 ). The mean (SD) age at first hospitalisation and rehospitalisation was 45.1 (16.5) and 47.6 (16.3) years, respectively, with no sex differences (P ¼ 0.66 and P ¼ 0.93, respectively). Of all hospitalised FH patients, 45.7% had FH recorded at discharge. The FH diagnosis was recognised more frequently in men (50.3%) than in women (41.0%) (P < 0.001) ( Table 2) .
The reported comorbidities among the hospitalised FH patients at discharge are summarised in Table 3 . CHD was most common (46.8%), followed by acute coronary syndrome (ACS) (25.2%). Altogether 89.6% of all hospitalised FH patients had ischaemic heart disease (CHD, AMI and ACS), of which there were more men (P < 0.001). Comorbidity due to heart failure (HF), atrial fibrillation/flutter (AF) and aortic aneurysm (AA) was also more prevalent among FH men than FH women (P 0.04).
The numbers of hospitalisations in the 1411 FH patients in relation to sex and the different diagnoses and CVD diagnostic procedures are given in Table 4 , with results of age-adjusted analysis. FH men had higher odds of CVD hospitalisations than FH women (P < 0.001), and of hospitalisation due to CHD, ACS, AMI, AA, HF, AF and PCI (P < 0.001). There were no significant sex differences in hospitalisations with CABG or coronary angiography. Table 5 displays CVD hospitalisations in relation to attained age intervals (significant interaction between age and sex, P interaction < 0.001). Most hospitalisations were in the age group 40-59 years. FH men had higher odds of hospital stays due to CVD in all age groups as compared to FH women (P < 0.001). However, the sex differences were smaller in patients 70 years of age or older.
Discussion
FH patients were first time hospitalised for CVD at a mean age of 45.1 years. In the general population the mean age was 64.9 years in the same time period. 16 We observed no sex differences in the mean age at first hospitalisation, which are important novel findings. Women were significantly older at the time of genetic FH diagnosis compared with men, indicating a delayed initiation of statin treatment in FH women.
Despite FH being a contributing factor to CVD events, less than half of the hospitalised patients had FH registered as any diagnosis at discharge. This finding is important, implying either patients' unawareness of reporting FH once admitted with CVD, or physicians' ignorance of FH, not asking the patient.
Re-admission rates are considered a measure of healthcare quality. 18, 19 Most FH patients (80%) had one or more hospital re-admissions, which are in accordance with a recent study demonstrating that 70% of FH patients had experienced one or more myocardial infarctions at time of death. 9 The high number of re-admissions underscores the importance of early interventions and follow-ups. Although CVD re-hospitalisations are common, accounting for 29.3% of all cases in Europe, 19 it seems they are more frequent in the FH population.
Whereas most hospitalisations in Norway are acute admissions (68.0%), 4 elective hospitalisations dominated (60.6%) among the FH patients. Elective readmissions are usually due to scheduled coronary angiography, PCI or CABG. 18 However, we found no differences in these procedures in the hospitalised FH patients compared with the general population, which could be related to the high numbers of elective hospitalisations. 16 Re-admissions may also vary according to the length of index stay, residence, sex, age, comorbidity, 18 or may be due to complications such as arrhythmias, bleedings and re-infarctions. 20 Once CVD is established in young age, higher re-admission rates are expected, 19 and efforts to reduce re-admissions should be targeted at FH patients at high risk of CVD. 20 During 1991-2000, the number of AMI hospital admissions in Norway declined by 18%, but from 2000 an increment by 33% was reported, which was mainly due to changes in the diagnostic criteria for AMI with the introduction of cardiac troponins. 21 Moreover, there was an increment of patient transfers between hospitals due to a higher number of coronary invasive procedures. 21, 22, 23 The number of patients who underwent PCI and CABG increased during 2001-2009 in all age groups, 24 of which men had the highest numbers. 24 In the present study FH men had significantly more hospitalisations with PCI compared to FH women. There were no sex differences in hospitalisations due to CABG and coronary angiography, suggesting that CVD risk differs less in FH patients in relation to sex than was found in the general population, but the total number of observations (14) was too low for statistical comparison. 16 Furthermore, the overall few numbers of diagnostic invasive procedures reflect the time period this study covered. From 2000 and onwards rates of myocardial infarction declined. 25, 26 During 2003-2012 coronary revascularisation declined by 40%, with most rapid declines in elective PCI and CABG. 26 We recently reported that 88% of the deceased FH patients in this cohort used statins but did not reach recommended LDL-cholesterol target values. 8 In the present study the hospitalised FH patients were about 18 years older at the time of diagnosis compared to those who had not been hospitalised, clearly demonstrating the negative impact of a late diagnosis on CVD morbidity. In a subgroup of 4688 patients in this cohort those who died were about 20 years older at time of genetic diagnosis than the survivors (mean 54.8 versus 33.6 years). 8 A meta-regression analysis of 25 trials reported a significant positive relationship between reduction in LDL-cholesterol and a reduction in CVD risk. 27 Notably, statin adherence is associated with a reduction in CVD-related hospitalisations and subsequent healthcare costs. 28 
Strengths and limitations
Important strengths of this study were the high number of genotyped FH patients and the complete follow-up. Although mean age in the FH cohort was slightly younger than in the Norwegian population in the same time period, 8 the link to CVDNOR gave corresponding data from the Norwegian population from the exact same time period. As all CVD hospitalisations from the entire Norwegian population during 1994-2009 were included, potential selection biases were minimised.
The present study may have underestimated the CVD morbidity in the FH population because undiagnosed individuals are not accounted for. Some may not have been hospitalised for different reasons such as out-of-hospital deaths or CVD misdiagnosed as other disorders.
CVDNOR did not provide information on pharmaceuticals, or data on physician follow-ups. Nor were there available data on AMI subtypes. Important factors that could influence CVD morbidity and hospitalisation frequencies were not accounted for, that is, smoking habits, body mass index, LDL-cholesterol values, statin treatment, dietary habits or participation in CVD rehabilitation programmes after discharge. However, in a study of 956 patients in this cohort 89.1% of those aged 18 years and above used lipid-lowering drugs and the mean levels of total serum cholesterol and LDL-cholesterol were 5.7 (1.5) mmol/L and 3.9 (1.3) mmol/L, respectively. 29 Furthermore, our study was mainly limited to a Caucasian population in which 92.4% of the patients in the FH cohort were native Norwegians. 15 In conclusion, Norwegian FH patients are first time hospitalised at the age of 45.1 years with no significant sex differences in mean age at first hospitalisation, which are important novel findings. Ischaemic heart disease was present in about 90% of all hospitalised FH patients. Once admitted with CVD, FH was registered in less than half of the hospital records at discharge, suggesting a huge unawareness of FH in Norwegian hospitals.
